October 22, 2013 | Israeli biomed company Neuroderm, which is developing a transdermal drug delivery system, is in the process of raising $5 million. “Globes” reports that the funds are being raised from current investors and new foreign investors.
The proceeds will be used to accelerate clinical trials and for a review of a possible IPO on Nasdaq in 2014.
Related posts
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023
ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments